Compile Data Set for Download or QSAR
Report error Found 38 Enz. Inhib. hit(s) with all data for entry = 6503
TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM134239(US8846673, 217)
Affinity DataIC50: 0.700nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/3/2015
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM134247(US8846673, 245)
Affinity DataIC50: 1nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/3/2015
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM134240(US8846673, 219)
Affinity DataIC50: 1nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/3/2015
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM134242(US8846673, 225)
Affinity DataIC50: 1nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/3/2015
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM134237(US8846673, 193)
Affinity DataIC50: 1nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/3/2015
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM134245(US8846673, 238)
Affinity DataIC50: 2nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/3/2015
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM134246(US8846673, 242)
Affinity DataIC50: 2nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/3/2015
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM134241(US8846673, 223)
Affinity DataIC50: 2nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/3/2015
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM134251(US8846673, 262)
Affinity DataIC50: 2nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/3/2015
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM134238(US8846673, 216)
Affinity DataIC50: 2nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/3/2015
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM134248(US8846673, 249)
Affinity DataIC50: 3nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/3/2015
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM134243(US8846673, 236)
Affinity DataIC50: 3nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/3/2015
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM134244(US8846673, 237)
Affinity DataIC50: 4nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/3/2015
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM134233(US8846673, 130)
Affinity DataIC50: 230nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/3/2015
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM134231(US8846673, 120)
Affinity DataIC50: 240nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/3/2015
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM134235(US8846673, 137)
Affinity DataIC50: 240nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/3/2015
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM134225(US8846673, 95)
Affinity DataIC50: 250nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/3/2015
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM134234(US8846673, 132)
Affinity DataIC50: 260nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/3/2015
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM134236(US8846673, 155)
Affinity DataIC50: 260nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/3/2015
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM134222(US8846673, 62)
Affinity DataIC50: 270nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/3/2015
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM134249(US8846673, 250)
Affinity DataIC50: 280nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/3/2015
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM134224(US8846673, 92)
Affinity DataIC50: 280nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/3/2015
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM134226(US8846673, 96)
Affinity DataIC50: 280nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/3/2015
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM134232(US8846673, 128)
Affinity DataIC50: 290nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/3/2015
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM134250(US8846673, 255)
Affinity DataIC50: 290nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/3/2015
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM134214(US8846673, 5)
Affinity DataIC50: 290nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/3/2015
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM134215(US8846673, 17)
Affinity DataIC50: 8.64E+3nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/3/2015
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM134223(US8846673, 82)
Affinity DataIC50: 9.18E+3nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/3/2015
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM134218(US8846673, 43)
Affinity DataIC50: 9.31E+3nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/3/2015
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM134217(US8846673, 31)
Affinity DataIC50: 9.41E+3nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/3/2015
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM134219(US8846673, 44)
Affinity DataIC50: 9.49E+3nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/3/2015
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM134228(US8846673, 107)
Affinity DataIC50: 1.27E+4nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/3/2015
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM134230(US8846673, 113)
Affinity DataIC50: 1.38E+4nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/3/2015
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM134227(US8846673, 102)
Affinity DataIC50: 1.40E+4nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/3/2015
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM134221(US8846673, 61)
Affinity DataIC50: 1.49E+4nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/3/2015
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM134229(US8846673, 108)
Affinity DataIC50: 1.61E+4nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/3/2015
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM134216(US8846673, 20)
Affinity DataIC50: 2.79E+4nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/3/2015
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM134220(US8846673, 47)
Affinity DataIC50: 4.06E+4nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/3/2015
Entry Details
US Patent